Publications by authors named "Amy Meng"

Claim this Profile
E
Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Amy Meng, Kacey Anderson, Cara Nelson, Liyun Ni, Shu-Min Chuang

Br J Clin Pharmacol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.
Amy Meng, Rita Humeniuk, Juliane M Jürgensmeier, Chia-Hsiang Hsueh, Franziska Matzkies

Clin Pharmacol Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Paqui G Traves, Bernard Murray, Federico Campigotto, René Galien, Amy Meng

Ann Rheum Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
Sergio M Borgia, Janet Dearden, Eric M Yoshida, Stephen D Shafran, Ashley Brown, Amy Meng

J Hepatol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 First-in-Human, Single- and Multiple-Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection.
Polina German, Yan Xin, Jason W Chien, Winnie Weng, Richard Mackman, Amy Meng

J Clin Pharmacol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis